Digital Microscopy-based Malaria Diagnostic Solution, miLab™ MAL

Product Inquiry

miLab™ MAL was introduced in UNITAID's report in 2022 as an innovative product that overcomes the limitations of current malaria diagnosis.

The Most Advanced Digital Microscope and Fully Integrated Bench-top Platform

miLab™ MAL, the malaria diagnostic solution is getting attention from the international community as an innovative malaria diagnostic product that overcomes the limitation of rapid diagnosis testing and manual microscopic diagnosis. miLab™ MAL was introduced in UNITAID’s annual report* as an innovative product that will enter scale-up level.

* Malaria Diagnostics Market and Technology Landscape, 4th
World Malaria Report 2022

miLab™ MAL focuses on overcoming the limitations of traditional diagnostics for malaria elimination in the world.

Malaria is one of the deadliest infectious diseases that international society, including the UN and WHO, announced will end the epidemics by 2030.

Global Malaria Issue Overview

* Year 2022

  • Number of malaria
    cases in the world
    250 million
  • Number of infants and
    children under age 5 among
    malaria deaths
  • Number of countries with
    84 countries
  • Percentage of global
    outbreaks that took place in
  • Global annual malaria
    eradication program
    $4.1 billion
  • Number of malaria deaths in
    the world

The World’s Only Diagnostic Testing Solution with the Accuracy of a Diagnostic Laboratory and the Accessibility of Rapid Diagnostic Tests

Performs Qualified Microscopy Test without Investment on Additional Infrastructure and Experts
Based on proven AI technology, miLab™ MAL performs accurate diagnostic tests at the level of qualified microscopists. In addition, it is easy to use the miLab™ with only about two hours of training. miLab™ Viewer allows the experts to review with remote access if an additional review is necessary.
Morphological Diagnosis Method, Independent of pfhrp2/3 gene deletions Issue
Unlike RDT that determine infection by antigen-antibody reactions, miLab™ MAL utilizes a morphological diagnostic approach. This allows for accurate diagnostic testing regardless of the presence of pfhrp2/3 deletions, which are currently spreading across Africa.
Support of In-depth Analysis of Malaria Parasite Species Pre-Classification and Life Cycle Stage
Through AI morphology analysis, miLab™ allows users to check the pre-classification of species and life cycle stage information. Based on this, it is possible to provide accurate treatment and monitoring of malaria-infected patients.
Provides Quantitative Parasitemia Numerical Analysis
Through analysis of 100K~300K red blood cells, which is more than 100 times more than the number checked by microscopists, it is possible to provide a more reliable parasitemia level estimate.

miLab™ MAL Delivers Differentiated Value in Terms of Improved Accessibility and Workflow Improvements Based on the User’s Needs.

1. Regions with a High Proportion of Imported Malaria Infections (North America, Europe, Middle East, etc.)
Target customer
National malaria diagnostic laboratory in the countries with no indigenous malaria infection.
Expected Value
Improved workflow allows lower labor costs and higher operational efficiency
In high income countries like the United States, there is not much demand for malaria diagnostic testing because there are no Indigenous malaria infections. Nevertheless, malaria is an infectious disease managed at the national level and national diagnostic laboratories must have malaria diagnostic testing capabilities. In addition, since cross-border travel is increasing as the world recovers from COVID-19, malaria infections risks are also growing.
Diagnostic labs need to hire high quality microscopists, but only a few have expertise and abundant experience in diagnosing malaria due to the low demand for the tests. In addition, labor costs for diagnostic testing have risen rapidly worldwide due to COVID-19, and the burden of hiring experts in areas where diagnostic test demand is low has increased. In fact, in high-income countries, the number of malaria diagnostic professionals is gradually decreasing.
The diagnostic laboratory experiencing difficulties in securing and hiring malaria experts, can secure malaria diagnostic test capabilities by introducing miLab™ MAL. Even without malaria experts, they can easily ask the malaria experts of another diagnostic laboratory to remotely review the digital image captured by the miLab™ platform. In diagnostic laboratories with malaria experts, introducing miLab™ MAL allows them to diagnose with high operational efficiency. This is because the miLab™ platform automatically performs all processes from sample prep, digital imaging, and AI analysis for malaria diagnosis.
Customers can expect to improve their workflow with the introduction of miLab™ MAL, which reduces labor costs and improves efficiency.
2. Regions with a High Proportion of Indigenous Malaria Infections. (Africa and Latin America)
Target customer
Diagnostic laboratory conducting malaria diagnostic tests in low and middle-income countries with a high incidence of malaria.
Expected Value
Increased reliability of diagnostic results by improved workflow.
The quality of the microscopic test, a gold standard method for malaria diagnosis, is affected by the proficiency of the experts. This is because the microscopic test is performed manually over eight or more complex steps, including blood smear, staining, and washing. Therefore, in order to maintain the quality of the microscopic test consistently, it is essential to secure experts with the experience and skills to perform it professionally.
In most African countries, where malaria cases are high, it is not easy to secure experts with abundant experience and accurate expertise in microscopic tests. This is because they cannot afford to have the facilities and infrastructures to systematically train experts. Many diagnostic laboratories in Africa are conducting microscopic tests; they are having difficulty securing stable quality, with large variations in test results depending on the proficiency of the microscopists. In particular, the deviation of the test results is actually malaria-positive, but the test results are often found in false negative, since it’s easy to identify the presence of malaria-infected cells, but much harder to confirm the absence of malaria-infected cells.
Diagnostic laboratories struggling to manage the quality of malaria diagnostic tests due to inconsistency in the proficiency of experts, can increase the reliability of diagnostic tests by introducing miLab™ MAL. In particular, for the results of malaria-negative reading by experts, they can conduct the second test with miLab™ to verify the results. Additionally, the miLab™ platform can support microscopists’ training with various sample types stored as digital result data.
miLab™ MAL users can expect to provide more accurate results and treatment to patients by improving the expertise of microscopists and increasing the reliability of the test results.
3. Regions with Where pfhrp2/3 gene deletions Occur
Target customer
Health facilities that perform malaria diagnostic tests using rapid diagnostic kits in the areas where pfhrp2/3 gene deletions occur.
Expected Value
Provide accurate diagnostic results even in health facilities with no experts through improved diagnostic accessibility.
Most African countries with a large number of malaria cases rely more on rapid diagnostic kits than microscopic diagnostic tests. International public procurement agencies such as the Global Fund are also purchasing rapid diagnostic kits as malaria diagnostic testing tools and distributing them to African countries. Many of the malaria rapid diagnostic tests currently available on the market are based on the detection of HRP2. However, there has been an increase in reports of pfhrp2/3 deletions in a significant number of African countries recently.
Diagnostic laboratories struggling to manage the quality of malaria diagnostic tests due to inconsistency in the proficiency of experts, can increase the reliability of diagnostic tests by introducing miLab™ MAL. In particular, for the results of malaria-negative reading by experts, they can conduct the second test with miLab™ to verify the results. Additionally, the miLab™ platform can support microscopists’ training with various sample types stored as digital result data.
Health facilities located in areas where pfhrp2/3 deletions are spreading can maintain malaria diagnostic testing services by introducing miLab™ MAL instead of using the unreliable rapid diagnostic kits. miLab™ MAL can be used after some simple training so local healthcare workers who do not have expertise in microscopic diagnosis can easily use it.
With the introduction of miLab™ MAL, users can expect to provide patients a reliable microscopic diagnostic solution with their existing workforce.
4. Regions Where Mixed Infection Cases Occurred (Latin America, Southeast Asia, etc.)
Target customer
Health facilities that perform malaria diagnostic tests using rapid diagnostic kits in areas where multiple malaria parasite infections are observed.
Expected Value
Improved diagnostic accessibility to provide accurate diagnostic test results and to strengthen the surveillance system.
In addition to African countries, malaria is also occurring in Latin America and Asia. Malaria parasites found in African countries are mainly P.falciparum, but there are other species such as P.vivax, P.knowlesi, P.ovale, and P.malariae in Latin America and Asia. Since there are differences in biological characteristics depending on malaria parasite species, there are differences in symptoms, diagnosis and treatment for each species. Currently, more than two malaria species are found in more than 30 countries around the world, and other parasite species are reported in countries where only P.falciparum has been previously found.
The rapid diagnosis kit is effective in checking for infection of a single species with a large number of cases, such as P.falciparum and P.vivax, but has the limitation that it cannot be used for mixed infections of two or more species or in the diagnosis of other species. Therefore, in countries where more than two species are found, the antigen antibody based RDT result reliability decreases. In particular, there is a high risk of spread of new malaria parasite species in border areas with large population movement or in dense forest areas where accurate diagnostic tests are not available.
In areas where multiple malaria parasite infections are observed, morphological characteristics of parasite species can be confirmed with the introduction of miLab™ MAL in health facilities.
Customers can expect that the miLab™ MAL will accurately identify the malaria species infecting patients. In addition,new species can be quickly confirmed at the border aiding national infectious disease monitoring of malaria.
5. Special Situation
Malaria is an infectious disease that occurs widely in 84 countries around the world, and there is a risk of malaria infection in special environments such as military bases, ships, rainforests, conflict zones, and refugee camps. miLab™ MAL is a digital microscope platform that enables accurate and rapid malaria diagnosis even in special situations where infrastructure and professionals are insufficient. We continue to develop our products so that they can be easily used in any environment where malaria diagnosis is needed. Contact us for more information on using miLab™ MAL in special situations.
  • Ethiopia/Ghana Patients can be treated quickly with accurate diagnostic tests.

    There are many cases of finding malaria-infected patients on the miLab™ platform that local experts have not found in Ethiopia's clinical sites. Because miLab™ is easy and simple to use, it's a must-have product in the clinical field

    by Cristian Koepfli, Ph.D.
    Assistant Professor of University of Notre Dame

    Sensitivity 94.3%, specificity 94% for P. falciparum. Sensitivity 97%, specificity 97.6% for P. vivax.
    Out of 52 P. falciparum infections in Ethiopia, 51 cases with pfhrp2/3 deletions were correctly identified as positive with miLab.
    (A digital microscope for the diagnosis of Plasmodium falciparum and Plasmodium vivax parasites, including P. falciparum with hrp2/hrp3 deletion, ASTMH Poster Session, 2023)


200,000 RBCs
in 15 min.

miLab™ MAL Specification
Sample Preparation
Staining method Modified Romanowsky
Sample type Venous or finger-prick blood
Sample volume 5μl
Focusing Multi-focus images acquired
Image count Acquires max. of 300,000 RBCS
Species suggestions Plasmodium falciparum (Pf)
Plasmodium vivax (Pv)
Plasmodium spp. (MP)
Stages suggestions Gametocyte, Schizont, Ring / Trophozoite
Count Suspected RBC, Total RBC
Parasitemia level %, Suspected RBC/μl
Viewing Functions Field view
Multi-focus view (10 vertical-planes)
Total Test Time
Avg. 15 mins
Remote Review
Viewing Functions Field View, Cell View, Cell Reclassification, Report
Product Code
Product Code
miLab™ Platform DMLA
miLab™ Cartridge MAL CMAA
miLab Viewer™ SMVA
SafeFix™ CSFA
miLab™ Slide Case ASCA